Emtricitabine

Treatment of HIV Infection

Emtricitabine is used in combination with other antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1) in adults and children. It is part of a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs). It works by slowing the growth of the virus, which helps decrease the amount of HIV in the body and allows the immune system to function better.

Prevention of HIV (PrEP)

When combined with certain other medications, emtricitabine is used for pre-exposure prophylaxis (PrEP). This use is intended to reduce the risk of acquiring HIV-1 infection in individuals who are HIV-negative but are at high risk of exposure to the virus through sexual activity.

Important Considerations

• Not a cure: Emtricitabine is not a cure for HIV or acquired immunodeficiency syndrome (AIDS).
• Transmission: While it helps manage the virus, taking this medication does not prevent the spread of HIV to others through sexual contact or exposure to blood.
• Combination therapy: For the treatment of an existing HIV infection, emtricitabine must be used as part of a multi-drug regimen and should not be used alone.

Mechanism of Action

Emtricitabine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). It works by interfering with an enzyme called reverse transcriptase, which the human immunodeficiency virus (HIV) requires to replicate and create new copies of itself.

When the drug blocks this enzyme, it helps to:

• Decrease the amount of HIV in the blood, also known as the viral load.
• Increase the number of CD4 cells, which are white blood cells that help the immune system fight infections.
• Slow the progression of the virus and reduce the risk of developing complications related to HIV.

Prevention and Treatment

In addition to treating existing HIV infections, emtricitabine is used as part of pre-exposure prophylaxis (PrEP). In this role, it helps prevent the virus from establishing a permanent infection if a person is exposed to HIV.

It is important to note that while emtricitabine helps control the virus, it is not a cure for HIV or AIDS. It must be taken consistently, usually as part of a combination therapy with other medications, to remain effective and prevent the virus from becoming resistant to treatment.

Common Side Effects

Many people taking emtricitabine experience mild side effects. These may include:

• Headache
• Diarrhea or nausea
• Dizziness or tiredness
• Difficulty falling asleep or staying asleep
• Strange or unusual dreams
• Skin rash
• Changes in skin color, such as darkening or spots on the palms of the hands or soles of the feet
• Cough or runny nose

Serious Side Effects

While less common, some side effects can be serious. Contact a healthcare provider immediately if you experience:

• Lactic acidosis: Symptoms include unusual muscle pain, stomach pain with nausea and vomiting, feeling cold (especially in the arms and legs), feeling dizzy or lightheaded, or a fast or irregular heartbeat.
• Liver problems: Symptoms include yellowing of the skin or the whites of the eyes, dark-colored urine, light-colored bowel movements, or pain in the upper right side of the stomach area.
• Kidney problems: Signs may include new or worsening bone pain, or changes in how much you urinate.
• Immune system changes: As the immune system gets stronger, it may react to old or hidden infections. Tell your doctor if you notice new symptoms like fever, swollen glands, or night sweats.

Hepatitis B Flare-ups

For individuals with both HIV and hepatitis B virus (HBV), stopping emtricitabine may cause a severe worsening of the hepatitis B infection. Liver function is typically monitored closely for several months after discontinuing the drug to check for signs of liver damage.

Lactic Acidosis and Liver Enlargement

A serious condition called lactic acidosis (a buildup of acid in the blood) and severe liver enlargement with fatty deposits (steatosis) can occur during treatment. This is a medical emergency that requires immediate attention. Symptoms may include unusual tiredness, muscle pain, difficulty breathing, stomach pain with nausea and vomiting, or feeling cold.

Kidney Function

Emtricitabine is primarily cleared by the kidneys. New or worsening kidney impairment can occur during treatment. Healthcare providers often perform blood tests to check kidney function before starting the medication and periodically during therapy.

Immune Reconstitution Syndrome

As the immune system strengthens during treatment, it may react strongly to previous or hidden infections, such as pneumonia, herpes, or tuberculosis. This inflammatory response can cause new symptoms shortly after starting HIV medication.

Bone Health

Some patients may experience a decrease in bone mineral density, which can increase the risk of thinning bones or fractures. This risk may be more significant when emtricitabine is used in combination with certain other antiviral medications.

Fat Redistribution

Changes in body fat distribution may occur in some people taking antiviral medications. This can include a loss of fat from the arms, legs, and face, or an increase in fat in the neck, breasts, and trunk.

Pregnancy

If you are pregnant or planning to become pregnant, talk to your healthcare provider about the risks and benefits of using emtricitabine. For individuals with HIV, it is important to control the virus during pregnancy to prevent transmission to the baby. Emtricitabine is often used as part of a combination therapy for this purpose.

There is a pregnancy registry that monitors the health of individuals and their babies when antiretroviral medications are used during pregnancy. Your doctor can provide more information on how to participate in this monitoring program.

Breastfeeding

In areas where safe water and infant formula are available, health experts generally recommend that individuals with HIV do not breastfeed. This is to avoid the risk of passing the virus to the baby through breast milk. Emtricitabine passes into breast milk, and there is limited data regarding its safety for nursing infants. If you are taking this medication for HIV prevention (PrEP), consult your doctor about the risks of breastfeeding.

Available Dosage Forms

Emtricitabine is primarily available in the following forms for oral administration:

• Capsules: These are taken by mouth, usually once per day.
• Oral Solution: This is a liquid form of the medication, often used for children or individuals who have difficulty swallowing capsules.

In addition to being available as a single-ingredient medication, emtricitabine is frequently combined with other antiretroviral drugs into a single tablet. These combination products are used to simplify treatment regimens by reducing the number of pills a person needs to take.

FDA Approval and Indications

Emtricitabine is approved by the U.S. Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is used in combination with other antiretroviral medications for both adults and children. Additionally, when used in combination with tenofovir, it is approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in individuals at high risk.

Boxed Warnings

The FDA has issued boxed warnings for emtricitabine regarding the following serious risks:

• Hepatitis B Exacerbation: Patients coinfected with HIV-1 and hepatitis B virus (HBV) may experience severe, acute worsening of hepatitis B if they discontinue emtricitabine. Liver function must be closely monitored for several months in these patients after stopping treatment.
• Drug Resistance: When used for PrEP, emtricitabine must only be prescribed to individuals who are confirmed to be HIV-negative. Using the medication for prevention in someone with an undiagnosed HIV infection can lead to the development of drug-resistant HIV-1 strains.

Regulatory Requirements

To mitigate the risk of drug resistance, regulatory guidelines require healthcare providers to confirm a negative HIV-1 test immediately before starting emtricitabine for PrEP and at least every three months while the patient continues the preventive regimen. Regular screening for other sexually transmitted infections is also recommended during use for PrEP.

Generic and Brand-Name Options

Emtricitabine is available as a generic medication. Generic drugs are typically less expensive than brand-name versions while containing the same active ingredients and providing the same clinical benefits.

Insurance Coverage

Most health insurance plans, including Medicare and Medicaid, provide coverage for emtricitabine. The specific out-of-pocket cost, such as a copayment or coinsurance, will vary depending on the individual's insurance provider and the specific plan's drug list (formulary).

Pharmacy Pricing

The retail price of emtricitabine can vary between different pharmacies. Patients may find different prices at local retail pharmacies compared to mail-order services. Comparing prices or using pharmacy discount programs may help reduce the total cost.

Financial Assistance

For individuals who are uninsured or have high out-of-pocket costs, financial assistance programs may be available. Some pharmaceutical manufacturers offer patient assistance programs or copay cards to help eligible individuals afford their medication. Additionally, some non-profit organizations offer support for those needing HIV treatment or prevention medications.